Wall Street Expects Editas Medicine to Soar 53%. Is It Time to Buy Now?

Investors looking for stocks that can produce dramatic gains in a short amount of time will want to turn their heads toward the biopharmaceutical space. Chasing short-term gains isn't the smartest way to invest, but hardly a month goes by without at least one stock from this industry shooting through the roof as the drugs it develops cross important milestones.The average Wall Street analyst following Editas Medicine (NASDAQ: EDIT) thinks the gene therapy stock can reach $3.25 per share in the next year. From recent prices, this implies a gain of about 53% over the next 12 months.Shares of Editas Medicine have more than doubled since briefly falling below $1 per share in April. Before rushing out to buy the stock in hopes it can surpass analysts' estimates and double investors' money again, you should know the stock has fallen more than 97% from the peak it set in 2021. What can investors make of all this?Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool